High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention

European Journal of Clinical Investigation

Volumn 40, Issue 2, 2010, Pages 139-147

  Walters, D L ^a   Ray, M J ^a   Wood, P ^a   Perrin, E J ^a   Bett, J H N ^a   Aroney, C N ^a  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Acute coronary syndrome; Enoxaparin; Percutaneous transluminal angioplasty; Platelet; Stents; Tirofiban

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; C REACTIVE PROTEIN; CD40 LIGAND; CLOPIDOGREL; D DIMER; DUAL SPECIFICITY PHOSPHATASE 2; ENOXAPARIN; HEPARIN; PADGEM PROTEIN; PROTHROMBIN; TIROFIBAN; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ADULT; ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; INFLAMMATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTHROMBIN TIME; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; VENOUS BLOOD;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, BALLOON; ANTICOAGULANTS; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; CD40 LIGAND; ENOXAPARIN; FEMALE; FLOW CYTOMETRY; HEPARIN; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TYROSINE;

EID: 75149130574     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2009.02237.x     Document Type: Article

References (37)

1. Cohen M, Diez JE, Levine GN, Ferguson JJ III., Morrow DA, Rao SV et al. Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report - III. J Invasive Cardiol 2007 19 : 525 538. quiz 539-40.
2. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008 51 : 210 247.
3. Brieger D, Van de Werf F, Avezum A, Montalescot G, Kennelly BM, Granger CB et al. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). Am Heart J 2007 153 : 960 969. (Pubitemid 46809853)
4. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004 292 : 45 54.
5. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006 355 : 1006 1017.
6. Kereiakes DJ, Montalescot G, Antman EM, Cohen M, Darius H, Ferguson JJ et al. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. Am Heart J 2002 144 : 615 624.
7. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999 100 : 1593 1601.
8. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992 327 : 141 145.
9. Antman EM, Cohen M, McCabe C, Goodman SG, Murphy SA, Braunwald E. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J 2002 23 : 308 314.
10. Gunasekara AP, Walters DL, Aroney CN. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention. Int J Cardiol 2006 109 : 16 20.
11. Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol 2004 44 : 14 9.
12. Danzi GB, Capuano C, Sesana M, Baglini R. Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement. Catheter Cardiovasc Interv 2004 61 : 179 184.
13. Michelson AD. Flow cytometry: a clinical test of platelet function. Blood 1996 87 : 4925 4936.
14. Stegnar M, Vene N, Bozic M. Do haemostasis activation markers that predict cardiovascular disease exist? Pathophysiol Haemost Thromb 2003 33 : 302 308.
15. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004 116 (Suppl. 6A 9S 16S.
16. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002 105 : 1760 1763.
17. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998 31 : 1460 1465. (Pubitemid 28273285)
18. Inoue T, Uchida T, Yaguchi I, Sakai Y, Takayanagi K, Morooka S. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Circulation 2003 107 : 1757 1763.
19. Kereiakes DJ, Runyon JP, Broderick TM, Shimshak TM. IIb's are not IIb's. Am J Cardiol 2000 85 : 23C 31C.
20. Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA 2000 97 : 6930 6932.
21. Phipps RP, Koumas L, Leung E, Reddy SY, Blieden T, Kaufman J. The CD40-CD40 ligand system: a potential therapeutic target in atherosclerosis. Curr Opin Investig Drugs 2001 2 : 773 777.
22. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998 391 : 591 594.
23. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2002 40 : 1366 1374.
24. Kereiakes DJ, Fry E, Matthai W, Niederman A, Barr L, Brodie B et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first". J Invasive Cardiol 2000 12 (Suppl. A 1A 5A.
25. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001 344 : 1888 1894.
26. Ray MJ, Crawford SA, Crawford RW, Jabur MK, Walters DL. Increased CD40 ligand expression on platelets is associated with cardiovascular events after total hip arthroplasty. J Thromb Haemost 2006 4 : 695 697.
27. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987 70 : 307 315.
28. Schmitz G, Rothe G, Ruf A, Barlage S, Tschȯpe D, Clemetson KJ et al. European Working Group on Clinical Cell Analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998 79 : 885 896.
29. Ray MJ, Walters DL, Bett N, Cameron J, Wood P, Aroney C. Point-of-care testing shows clinically relevant variation in the degree of inhibition of platelets by standard-dose abciximab therapy during percutaneous coronary intervention. Catheter Cardiovasc Interv 2004 62 : 150 154.
30. Ray MJ, Hawson GA, Just SJ, McLachlan G, O'Brien M. Relationship of platelet aggregation to bleeding after cardiopulmonary bypass. Ann Thorac Surg 1994 57 : 981 986.
31. Ware JA, Coller BS. Chapter 119 platelet morphology, biochemistry, and function. In : Beutler E, Lichtman MA, Coller BS, Kipps TJ, editors. Williams Haematology. New York : McGraw-Hill 2000 : pp. 1161 1201.
32. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Wan Y, Aggarwal A et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 2002 90 : 1421 1423. (Pubitemid 35449499)
33. Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001 103 : 2572 2578.
34. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001 38 : 1002 1006.
35. Ray MJ, Walters DL, Bett JN, Cameron J, Wood P, Aroney CN. Platelet-monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab. Int J Cardiol 2005 101 : 249 255.
36. Furman MI, Krueger LA, Frelinger AL, III., Barnard MR, Mascelli MA, Nakada MT et al. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost 2000 84 : 492 498.
37. Linnemann B, Schwonberg J, Mani H, Prochnow S, Lindhoff-Last E. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost 2008 6 : 677 683.